The site of acceptance

             
                                   Academician Sang Guowei (left third), accompanied by Dr. Lu Xianfeng, 
                                             GM Assistant of YRPG (left first), looks at the key medicines

             
                                           Academician Sang Guowei (left third) accompanied by Xu Jingren,
                                   Chairman of YRPG (right three), in Freeze Injection Powder No.2 Workshop

            
  Academician Sang Guowei (left) listens to General Manager Li Yin (right third) introduction to No.2 Workshop

On June 18, Academician Sang Guowei, member of NPC, Vice Director of NPC Science, Education, Culture and Health Commission and Director of Chinese Pharmaceutical Association, visited YRPG. Sang Weiguo conducted the acceptance of the research topic of “major pharmaceutical manufacturing and innovation?system building of innovative medicine and development”. Sun Ningsheng, Director of Education and Science Division of Jiangsu Health and Family Planning Commission, Li Yafang, Vice Director of Social Development Division of Jiangsu Science and Technology Department, Xu Jingren, Chairman of YRPG, Xu Haoyu, Vice Director, Lv Qiang, Chief Scientist, Lu Xianfeng, GM Assistant of YRPG and Zheng Lu were also on the site.
In the address, Xu Jingren said that on the one hand the company won state, provincial and local government support in finance and policy; on the other hand, YRPG has built its own research team and yielded its own results, with enhanced innovation ability. Mr. Xu said that through three years of effort, the company has completed major tasks of the research topic of system building of innovative medicine and development. YRPG has also made strides in discovery of new medicines, craftsmanship development, quality control, industrialization research, etc.
Mr. Sang Weiguo said that innovation should made more results and be more industrialized to promote economic growth. He noted that acceptance was aimed to summarize the major achievement of the “state major new medicine” program and provide suggestions in response to the shortcomings, promote biomedicine growth, and benefit the people in preventing and curing diseases. He hoped that YRPG could play a greater part in the 13^th Five-year Plan, and lead more companies to be involved in scientific innovation and the main body of scientific innovation.
At the acceptance conference, Lu Xianfeng, GM Assistant of YRPG reported on the overall progress of the research, completion of KPI targets and major achievements to experts’ effort and answered questions from them. The expert’s group examined the content of the research, overall targets, assessment indicators, etc. and also examined the clinic approval documents, new medicine certificates, manufacturing approval documents, patents, etc. Then, the expert group visited the state key lab of medicine and solution built by the group and some of the workshops. In the key lab, Academician Sang Guowei listened to the basic information of R&D and introduction to key products. Learning that scale and technical prowess of the research lab has become the first-class in China, the experts expressed their praise. In No.2 Workshop of freeze dry power injection, the experts watched video of the process in the shop floor. Sang Weiguo also asked about the basic conditions of the workshop and details of craftsmanship. In No.2 Extraction Workshop, the experts witnessed the layout, equipment and craftsmanship.
The system building of innovative pharmaceutical research and development is based on industry-university alliance, oriented to the design and discovery of innovative medicine; through the platform building of process control, industrialization, standards establishment, the company will build an alliance of giant pharmaceutical companies in modern time and enhance the ability to develop and industrialize.
Through this check, the experts have recognized the group’s ability in technical progress, innovation mechanism and professional team building. The acceptance was successful. The expert team also provided some advice based on the conditions. First, further enhance industry-research cooperation: manage and operate by the alliance model and improve the coordinated innovation ability and research with a center in company. Second, further focus on the topic, follow the latest development of innovative medicines in China and overseas and step up the development of major products; third, enhance the research and production of biomarkers and reagent.
The research topic covers 8 technical parks and industry-university alliances including Guangzhou Pharmaceutical Holdings Limited and China National Pharmaceutical Group Corporation in addition to Yangtze River Pharmaceutical Group.